- Language: English
- 312 Pages
- Published: February 2009
- Region: Global
Competitor Analysis: Proteasome Inhibitors
- Published: November 2009
- Region: Global
- 14 Pages
- La Merie Publishing
The present Competitive Intelligence Report about Proteasome Inhibitors provides a competitor evaluation in the field of novel small molecules and peptides targeting the proteasome for treatment of cancer as of November 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The proteasome is involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. Due to the importance of the proteasome in cellular functions, inhibition or activation of the proteasome could become a useful therapeutic strategy for a variety of diseases.
Many proteasome inhibitors have been identified and can be classified into two groups according to their source: chemically synthesized small molecules and compounds derived from natural products. A successful example of development of a proteasome inhibitor as a clinically useful drug is the peptide boronate, PS341 (Bortezomib). The drug was approved for the treatment of multiple myeloma. In contrast to proteasome inhibitors, small molecules that can activate or enhance proteasome activity are rare and are not well studied. Despite the commercial success of Velcade, the pipeline of novel proteasome inhibitors is not overcrowded which might indicate the difficulties in identifying new clinical candidates, but also offers a competitive advantage.
The report includes a compilation of current active projects in research and development of molecules targeting the proteasome. In addition, the report lists company-specific R&D pipelines of proteasome targeting small molecules and peptides. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Product Category,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information. SHOW LESS READ MORE >
- Velcade Pipeline
- Proteasome Inhibitors
- Corporate Proteasome Inhibitor R&D Pipelines
- About La Merie